Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Wakamoto to Set Up JV for Generics with Taiwan Drugmaker
May 2, 2011
- HSC Approves Draft Report on Measures against Rheumatism
May 2, 2011
- Moratorium on Copayment by Quake Victims to Be Extended: Korosho
May 2, 2011
- Kyowa Kirin Completes Legal Procedures for Acquisition of ProStrakan
May 2, 2011
- Chugai's Pegasys Granted Priority Review Status for CHB
May 2, 2011
- Outgoing KEIZAI DOYUKAI Chairman Expresses Hope for His Successor from Regulation-bound Industry
May 2, 2011
- Kaken to Achieve Its Operating Profits Goal: Mizuho Securities
May 2, 2011
- Gov't Designates Eribulin as Ad-restricted Drug
May 2, 2011
- Sugi HD: Sales from Dispensing Services Up 16% to ¥24.8 Bil.
May 2, 2011
- CoreMed Offers New Service to Increase Efficiency of eCTD Filing
May 2, 2011
- Korosho to Consider Allowing Home Delivery of OTC Drugs by Pharmacists
May 2, 2011
- FPMAJ Finalizes Voluntary Plan for Energy-saving this Summer
May 2, 2011
- Acronet, ICON to Collaborate in CRO Business
May 2, 2011
- OTC Ketotifen to be Reclassified as Class 2
May 2, 2011
- FPMAJ Proposes Rotating Production for Some Makers this Summer
May 2, 2011
- “Generally Favorable”Outlook for Dispensing Pharmacies in FY2011: Analyst
May 2, 2011
- What Is on the Mind of Japan's Pharmaceutical Executives?
May 2, 2011
- Quake-hit Plant to Return to Full Operation by Sept.: Chugai
May 2, 2011
- 33 Drugs Approved Including LIXIANA
May 2, 2011
- Bayer Starts Multinational PIII Trial for VEGF Trap-Eye in DME
May 2, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…